A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 965-971

  Monnereau Laborde, Sylvie ^a   Munzer, Caroline ^b   Valteau Couanet, Dominique ^c   Ansoborlo, Sophie ^a   Coze, Carole ^d   Chastagner, Pascal ^e   Rubie, Hervé ^b   Demeocq, François ^f   Stephan, Jean Louis ^g   Hartmann, Olivier ^c   Perel, Yves ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL D ENFANTS   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Clinical trials; Myeloablative therapy; Neuroblastoma

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROBLASTOMA; OVERALL SURVIVAL; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPTICEMIA; SKIN INFECTION; STAPHYLOCOCCAL BACTEREMIA; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEUROBLASTOMA; PILOT PROJECTS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 80052766144     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23232     Document Type: Article

References (28)

1. Matthay KK. Neuroblastoma: Biology and therapy. Oncology 1997; 11: 1857-1866 (1869-1872; 1875).
2. Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: A study of 487 cases. Br Med J 1974; 3: 301-307.
3. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Br J Cancer 1993; 67: 119-127.
4. Canete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009; 27: 1014-1019.
5. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.
6. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 2008; 9: 247-256.
7. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953-965.
8. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789-795.
9. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468-476.
10. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12: 2607-2613.
11. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001; 36: 227-230.
12. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005; 23: 532-540.
13. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 1997; 15: 3433-3440.
14. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
15. Hartmann O, Kalifa C, Benhamou E, et al. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 1986; 16: 165-169.
16. Valteau-Couannet D, Benhamou E, Vassal G, et al. Consolidation with busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937-942.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
18. Kanold J, Halle P, Rapatel C, et al. Safe and efficient peripheral blood stem cell collection in the smallest of children. Ther Apher 1998; 2: 49-57.
19. Grönroos MH, Jahnukainen T, Irjala K, et al. Comparison of glomerular function tests in children with cancer. Pediatr Nephrol 2008; 23: 797-803.
20. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991; 19: 295-300.
21. World Health Organization. WHO handbook for reporting results of cancer treatment. World Health Organisation Offset Publication, editor; 1979.
22. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2: 609-616.
23. Hartmann O, Benhamou E, Beaujean F, et al. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987; 5: 1205-1211.
24. Philip T, Bernard JL, Zucker JM, et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987; 5: 266-271.
25. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: Results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284-2292.
26. Pradhan KR, Johnson CS, Vik TA, et al. A Novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer 2006; 46: 793-802.
27. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
28. Kohler JA, Ellershaw C, Machin D, et al. Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers. Pediatr Blood Cancer 2007; 49: 234.